Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
Key facts
- Where
- Brussels, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05443516, who can take part
Where in Belgium
- Cliniques universitaires Saint-LucBrussels, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Trial code
- NCT05443516
- Record updated
- 5 July 2022
- Original description
The aim of this research project is to better understand the origin and clinical significance of two lupus-specific "genetic signatures" (IFN signature and plasma cell signature) in patient subgroups with well-defined clinical characteristics. Our aim is to correlate these genetic signatures with cell activation profiles and the production of specific cytokines in different populations from whole blood and in short-term cultures of these circulating cells.Read full original descriptionShow less
Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus. Recherche de Biomarqueurs de l'activité de la Maladie Chez Des Patients Atteints de Lupus érythémateux disséminé.
The aim of this research project is to better understand the origin and clinical significance of two lupus-specific "genetic signatures" (IFN signature and plasma cell signature) in patient subgroups with well-defined clinical characteristics. Our aim is to correlate these genetic signatures with cell activation profiles and the production of specific cytokines in different populations from whole blood and in short-term cultures of these circulating cells.
Inclusion: Fulfilment of the EULAR/ACR classification criteria of SLE; 18 years of age or above; Incident or Flare biopsy-proven proliferative or membranous LN.
Exclusion: Anticipated non-adherence to therapy; Antiphospholipid syndrome nephropathy (APSN); Medical conditions interfering with outcome evaluations; Pregnancy at baseline (pregnancy during follow-up will not lead to exclusion); Inability to read and/or sign the informed consent form.